Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

170
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
170
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

132
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
132
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

211
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
211
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

220
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
220
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

296
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
296

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recommendations for Assessing Methodological Quality in Systematic Reviews of Population Pharmacokinetic Models: A Systematic Review.

Therapeutic drug monitoring·2026
Same author

Fentanyl or Morphine for Persistent Dyspnea in COPD: a multicenter randomised cross-over trial.

The European respiratory journal·2026
Same author

A versatile and GMP-compliant bead-based IFN-γ potency assay for standardized quality control and release testing of CAR-T cell drug products.

International journal of pharmaceutics: X·2026
Same author

Physiological and Anatomical Alterations in Children with Liver Cirrhosis.

Pharmaceutical research·2026
Same author

Voriconazole therapy and CYP2C19 phenotype: identifying patients who may need alternative antifungal therapy.

The Journal of antimicrobial chemotherapy·2026
Same author

Adverse events in bedaquiline- and pretomanid-based regimens for drug-resistant tuberculosis from trial, implementation and pharmacovigilance studies.

British journal of clinical pharmacology·2026

Related Experiment Video

Updated: May 28, 2025

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.7K

Azithromycin as Host-Directed Therapy for Pulmonary Tuberculosis: A Randomized Pilot Trial.

Bart G J Dekkers1, Huib A M Kerstjens2, Helene W Breisnes3,4

  • 1Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

The Journal of Infectious Diseases
|February 11, 2025
PubMed
Summary

Azithromycin added to standard tuberculosis treatment reduced inflammation markers in patients. This adjunctive therapy appears safe and helps resolve systemic and pulmonary inflammation in tuberculosis.

Keywords:
azithromycinextracellular matrixhost-directed therapyinflammationtuberculosis

More Related Videos

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.8K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.5K

Related Experiment Videos

Last Updated: May 28, 2025

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.7K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.8K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.5K

Area of Science:

  • Immunology
  • Pharmacology
  • Infectious Diseases

Background:

  • Investigating host-directed therapies for tuberculosis (TB) to modulate immune responses and reduce inflammation.
  • Macrolides like azithromycin have anti-inflammatory and immune-modulatory properties alongside antibacterial effects.
  • Azithromycin's potential to enhance inflammation resolution and decrease tissue turnover in TB patients was explored.

Purpose of the Study:

  • To evaluate if azithromycin, as an adjunctive therapy, improves inflammation resolution in pulmonary tuberculosis.
  • To assess azithromycin's impact on systemic and pulmonary inflammation markers.
  • To determine if azithromycin affects extracellular matrix turnover in TB patients.

Main Methods:

  • An open-label, randomized controlled trial was conducted.
  • Adult patients with drug-susceptible pulmonary TB received standard care with or without azithromycin (250 mg daily) for 28 days.
  • Biomarkers of inflammation and tissue turnover were measured in blood and sputum.

Main Results:

  • Azithromycin significantly enhanced the reduction of interferon-γ-induced protein-10 (IP-10) in blood.
  • Treatment with azithromycin led to significant reductions in sputum neutrophils, neutrophil elastase, and transforming growth factor-β.
  • Azithromycin also significantly reduced the collagen degradation marker C4M in blood.
  • The addition of azithromycin to standard care was found to be safe.

Conclusions:

  • Adding azithromycin to standard tuberculosis treatment helps reduce neutrophilic inflammation in pulmonary TB.
  • Azithromycin shows promise as an adjunctive therapy for managing inflammation in tuberculosis.
  • Further research may explore azithromycin's role in improving clinical outcomes in TB patients.